Drug firm Indivior plans to move primary listing to US in snub to London

Indivior makes most of its revenue in the US, but the switch in its listing could prove a setback for its British business. Photograph: Piotr Swat/Alamy

Indivior, which makes the opioid addiction treatments Suboxone and Sublocade, is sounding out shareholders over plans to move its primary share listing to the US this year in the latest blow to London’s standing as an international financial centre.

Mark Crossley, the Indivior chief executive, said: “We are excited to announce that we are initiating consultations with shareholders on potentially transitioning to a primary listing in the US in 2024 while maintaining a secondary listing in the UK.”